Search
mitapivat (Pyrukynd)
Indications:
- treatment of hemolytic anemia in adults with pyruvate kinase deficiency
Contraindications:
- avoid if severe hepatic impairment
Dosage:
- start: 5 mg BID with or without food
- titrate* upward at 4 week intervals to maximum of 50 mg BID at 12 weeks
- taper to discontinue over period of 14 days
Tablets: 5 mg. 20 mg, 50 mg (swallow tablet whole)
* titrate to blood hemoglobin
Adverse effects:
- increased serum uric acid
- back pain, arthralgia
- hypertriglyceridemia
- gastroenteritis
- hypertension
- arrhythmia
- constipation
- dry mouth
- paresthesia
- acute hemolysis with abrupt discontinuation
Pharmacokinetics:
- metabolized by CYP3A4
Drug interactions:
- inducers & inhibitors of CYP3A4
Mechanism of action:
- pyruvate kinase activator
- allosterically binds to pyruvate kinase tetramer thus increasing pyruvate kinase activity
General
hematologic agent
Database Correlations
PUBCHEM correlations
References
- HIGHLIGHTS OF PRESCRIBING INFORMATION
PYRUKYND (mitapivat) tablets, for oral use
https://www.agios.com/prescribinginfo.pdf